ArticleBritish journal of cancer2026
Non-invasive biomarkers for early oral cancer detection through multiomics approach.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNon-invasive biomarker-based approaches are urgently needed to support early identification and monitoring of Oral squamous cell carcinoma (OSCC) and its precursor, oral submucous fibrosis (OSMF).
methodsWe employed combined metabolomic and proteomic analyses to profile saliva and lesion surface swabs from clinically diagnosed OSCC (n = 15), OSMF (n = 20), and healthy controls (n = 27). Polar and nonpolar metabolites were extracted separately from saliva, while proteins were isolated from exfoliated mucosal epithelial cells. Differential expression, pathway enrichment, and biomarker classification were performed across four comparisons: OSCC vs non-OSCC (controls + OSMF), OSCC vs OSMF, OSMF vs control, and OSCC vs control.
resultsDistinct molecular changes were observed across the health-to-cancer spectrum. Top discriminatory salivary metabolites included linoelaidic acid, gamma-glutamylcysteine, and 3-hydroxybutyryl-CoA, implicating dysregulated linoleic acid metabolism, redox imbalance, and fatty acid β-oxidation in pathogenesis. Proteomic data revealed significant upregulation of histone variants, cytoskeletal keratins, and BPI-fold-containing proteins in OSCC, reflecting chromatin remodelling and epithelial-mesenchymal transition. Multivariate biomarker panels achieved high accuracy (AUC ≥ 0.96) for classifying OSMF from OSCC.
conclusionOur combined metabolomic and proteomic profiling revealed non-invasive molecular signatures for early detection and monitoring of OSCC and OSMF.
Identifiers
42481686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.